Sharptx
1 known investors
Find your way into Sharptx
163 people in our graph share verified history with the Sharptx team — schools, employers, funds. One of them is your warm intro.
Mike Ghaffaryunlockedknows Scott Sneddon · together at Harvard Law School (overlapped)
×11knows the team · via Columbia Law School
Sharp Therapeutics develops a small molecule drug platform designed to treat genetic diseases more affordably and quickly than current biologics and gene therapies. The company targets patients and payors seeking faster, scalable alternatives to existing genetic disease treatments.
Founders & leadership
SS
Scott SneddoninCEOScott Sneddon holds training in chemistry and biology with computational expertise and has led drug discovery teams across large pharmaceutical and biotech companies, with particular experience in assay development and high-throughput screening. He holds a law degree and has managed business development activities including licensing and acquisition negotiations.
Investors · 1
Frequently asked questions
- What does Sharptx do?
- Sharp Therapeutics develops a small molecule drug platform designed to treat genetic diseases more affordably and quickly than current biologics and gene therapies. The company targets patients and payors seeking faster, scalable alternatives to existing genetic disease treatments.
- Who are Sharptx's investors?
- Sharptx's investors include Newlin Investment Company LLC.